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bypass grafting (CABG). Previous studies have reported prognosis in relation to treatment with or without insulin, and not
to the type of diabetes.
OBJECTIVES This study investigated long-term survival in patients with type 1 DM (T1DM) and type 2 DM (T2DM)
following CABG.
METHODS We included all patients from the SWEDEHEART (Swedish Web-System for Enhancement and Development of
Evidence-BasedCare inHeartDiseaseEvaluatedAccordingtoRecommendedTherapies) registerwhounderwentprimary isolated
CABG inSwedenduring2003through2013.We identiﬁedpatientswithT1DMorT2DMin theSwedishNationalDiabetesRegister.
We calculated hazard ratios (HRs) with 95% conﬁdence intervals (CIs) for all-cause mortality in patients with T1DM or T2DM.
RESULTS In total, 39,235 patients were included, of whom 725 (1.8%) had T1DM and 8,208 (21%) had T2DM. Patients
with TDM1 were younger (59 vs. 67 years), had reduced kidney function (31% vs. 24%), and had peripheral vascular
disease (21% vs. 11%) more often than patients with TDM2 or no diabetes. During a mean follow-up of 5.9  3.2 years
(230,085 person-years), 6,765 (17%) patients died. Among patients with T1DM, 152 (21%) died, and among patients with
T2DM, 1,549 (19%) died. Adjusted hazard ratio (95% conﬁdence interval) for death in patients with T1DM and T2DM,
compared with patients without diabetes, were 2.04 (1.72 to 2.42), and 1.11 (1.05 to 1.18), respectively.
CONCLUSIONS Patients with T1DM had more than double the long-term risk of death after CABG compared
with patients without diabetes. The long-term risk of death in patients with T2DM was only slightly increased.
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AB BR E V I A T I O N S
AND ACRONYM S
CABG = coronary artery bypass
grafting
CI = conﬁdence interval
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1645there is a doubling of the age-adjusted prevalence of
coronary heart disease, and the risk of death is be-
tween 2 and 4 times higher than in those without
DM (4,5). Approximately 25% of all U.S. patients
who undergo multivessel coronary revascularization
have DM (6).SEE PAGE 1653
DM = diabetes mellitus
HbA1c = glycosylated
hemoglobin
HR = hazard ratio
MI = myocardial infarction
PCI = percutaneous coronary
intervention
T1DM = type 1 diabetes
mellitus
T2DM = type 2 diabetes
tusT1DM and T2DM have different underlying patho-
physiology. T1DM is usually characterized by onset at
an early age, in which the underlying cause is auto-
immunity and destruction of the insulin-producing
b cells, leading to insulin deﬁciency. By contrast,
T2DM is characterized by an adult onset of hyper-
insulinemia that is due to insulin resistance and, as a
consequence, a slow progression of hyperglycemia.
T2DM is associated with obesity, and its incidence
increases with age (7,8).
A number of studies have investigated the impact
of DM on prognosis after coronary artery bypass
grafting (CABG) (9–12). The categorization of DM in
these studies has varied from dividing patients ac-
cording to only the presence or absence of DM (10–12)
to, more speciﬁcally, insulin-treated or not insulin-
treated diabetes (9). Results from these studies have
been conﬂicting: some demonstrating an association
with adverse outcome (11), and others ﬁnding no in-
dependent association with outcome (10,12). In an-
other study, it was reported that compared with
non–insulin-treated diabetes, those with insulin-
treated diabetes had an increased long-term risk of
death (9). To the best of our knowledge, there is only 1
study that has categorized CABG patients into T1DM
and T2DM (13). In that study, the authors found an
association with death and myocardial infarction (MI)
for both T1DM and T2DM.
On the basis of recent ﬁndings, the quality of care
has improved in patients with T1DM, and conse-
quently, there is a paucity of evidence regarding
prognosis in contemporary patients with T1DM and
coronary artery disease. Recently, the American Heart
Association and the American Diabetes Association
published a scientiﬁc statement calling for more
studies in patients with T1DM and cardiovascular dis-
ease (14). Consequently, we performed a nationwide
population-based cohort study in patients who un-
derwent CABG in Sweden over a period of 11 years to
investigate the importance of T1DM and T2DM
regarding the long-term risk of death.
METHODS
This observational, nationwide population-based
cohort study database was created by cross-linkingseveral national Swedish health data regis-
ters. The unique personal identity number
assigned to every Swedish citizen was used as
the identiﬁer in the records linkage proce-
dure at the Swedish National Board of Health
and Welfare. The database was then anony-
mized according to regulations. The personal
identity number and national registers are
described in the Online Appendix.
In brief, all patients who underwent pri-
mary isolated nonemergency CABG in Sweden
between 2003 and 2013 were included. The
study population and baseline characteristics
were obtained from the SWEDEHEART
(Swedish Web-System for Enhancement and
Development of Evidence-Based Care in Heart
Disease Evaluated According to Recommended Ther-
apies) register, and further expanded with informa-
tion from the National Patient Register, the Swedish
Renal Register, and socioeconomic data from Statis-
tics Sweden (a government agency) (15). Data sources
are described in detail in the Online Appendix. The
regional Human Research Ethics Committee, Stock-
holm, Sweden, approved the study.
DEFINITIONS OF DM. The type of DM (1 or 2) was
obtained from the Swedish National Diabetes Register
(Online Appendix). All patients who were not
included in the Swedish National Diabetes Register
were considered as being nondiabetic. The epidemi-
ological deﬁnition of T1DM was onset of DM at
age <30 years and treatment with insulin only (16).
T2DM was deﬁned as DM treated with diet or oral
hypoglycemic agents alone, or age >40 years at onset
and treated with insulin alone or in combination with
oral hypoglycemic agents (17).
OUTCOMES. We obtained the date and cause of death
from the national Cause of Death Register. Causes of
death were categorized as cardiovascular or non-
cardiovascular. Rehospitalization for MI, heart fail-
ure, stroke, or repeat revascularization (percutaneous
coronary intervention [PCI] or CABG) data were ob-
tained from the National Patient Register. A major
adverse coronary event (MACE) was deﬁned as hos-
pital stay for MI, stroke, heart failure, or revasculari-
zation. International Classiﬁcation of Diseases codes
for the outcome measures are shown in the Online
Appendix.
MISSING DATA. Missing data (renal function [4.5%],
ejection fraction [2.6%], body mass index [7.6%], edu-
cation [2.5%], number of bypass grafts [14%]) were
managed by multiple imputation (Online Appendix).
STATISTICAL METHODS. Patient characteristics were
described using frequencies and percents for
melli
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1646categorical variables, and means and standard de-
viations for continuous variables. The primary
outcome measure was death from any cause. Pa-
tients contributed person-time in days from the date
of surgery until the date of death from any cause or
the end of follow-up (March 24, 2014). Secondary
outcome measures included cardiovascular death,
and a combination of hospital stay for MI, heart
failure, stroke, or repeat revascularization. Informa-
tion regarding cause of death and hospital stay was
available until December 31, 2012; therefore, the
follow-up period for the secondary outcome mea-
sures ended on December 31, 2012. As a result,
patients who underwent surgery during 2013 (n ¼
2,473) were excluded from the secondary outcome
analyses.
We used Cox regression to estimate the risk of all-
cause mortality or a combined endpoint (all-cause
mortality or hospital stay for MI, heart failure, stroke,
or repeat revascularization) in patients with T1DM or
T2DM in a comparison with reference patients
without diabetes. We calculated crude and multivar-
iable adjusted hazard ratios (HRs) and 95% conﬁ-
dence intervals (CIs). We included all the variables
listed in Table 1 as covariates in the ﬁnal multivariable
model.
We investigated differences in each cause of mor-
tality (cardiovascular death or other causes) by
competing risk regression based on the Fine-Gray
proportional subhazards model (18), and calculated
subdistribution HR and 95% CI.
Data management and statistical analyses were
performed using Stata 13.1 (Stata Corp, College Sta-
tion, Texas) and R version 3.1.1 (R Foundation for
Statistical Computing, Vienna, Austria).RESULTS
Patient characteristics are presented in Table 1. A total
of 39,235 patients with a mean age of 67 years were
included, of whom 21% (8,170 of 39,235) were women.
In total, there were 23% (8,933 of 39,235) patients
with DM, of whom 1.8% (725 of 39,235) had T1DM and
21% (8,208 of 39,235) had T2DM. Patients with T1DM
were more likely to be younger, female, and have
chronic kidney disease, peripheral vascular disease,
and heart failure in comparison with patients with no
DM or T2DM.
During a mean follow-up time of 5.9  3.2 years
(230,085 person-years), in total, 17% (6,765 of 39,235)
patients died: 17% (5,064 of 30,302) with no DM, 21%
(152 of 725) with T1DM, and 19% (1,549 of 8,208)
with T2DM. The unadjusted Kaplan-Meier estimatedsurvival curve is shown in Figure 1, and the age-
adjusted survival curve is shown in Figure 2. The
crude incidence rate of death in patients with no DM,
T1DM, and T2DM was 28 (95% CI: 27 to 29), 39 (95%
CI: 33 to 45), and 33 (95% CI: 31 to 35) per 1,000
person-years, respectively. After 1 year of surgery,
survival was 97%, 96%, and 97% in patients with no
DM, T1DM, and T2DM, respectively. The correspond-
ing ﬁgures after 5 years were 89%, 85%, and 89%,
respectively. After multivariable adjustment, the HR
(95% CI) for death was 2.04 (1.72 to 2.42) in patients
with T1DM and 1.11 (1.05 to 1.18) in patients with
T2DM, compared with no DM. Furthermore, we
categorized causes of death into cardiovascular death
or noncardiovascular death. The point estimates
indicated a stronger association between T1DM and
noncardiovascular death than with cardiovascular
death. The association between T2DM and cardio-
vascular death was not signiﬁcant (HR: 1.08, 95% CI:
0.95 to 1.19).
When we analyzed death and MACE as a composite
outcome, the associations found were similar to those
for death alone, with nearly a doubling of risk in pa-
tients with T1DM and only a small increase in risk in
patients with T2DM (Central Illustration).
In a subset of patients with T1DM and T2DM
(n ¼ 8,933), we found that there was a signiﬁcantly
higher risk for all-cause mortality in T1DM com-
pared with T2DM (adjusted HR: 1.70 [95% CI: 1.40
to 2.06]). In 99.6% (8,899 of 8,933) of these pa-
tients, information regarding preoperative glycosy-
lated hemoglobin (HbA1c) and diabetes duration was
available. When HbA1c and duration of disease were
added to the multivariable model, the risk for all-
cause mortality in T1DM compared with T2DM was
slightly attenuated (adjusted HR: 1.44 [95% CI: 1.14
to 1.80]).
RELATIONSHIP BETWEEN TYPE OF DM, DURATION
OF DISEASE, AND GLYCEMIC CONTROL. Patients
with T1DM had a longer duration of disease than
patients with T2DM (mean 40.8 vs. 9.6 years)
(Table 2). In patients with T1DM, 94% had a longer
duration of disease than 20 years, compared with 10%
in patients with T2DM. Furthermore, patients with
T1DM had, in general, higher HbA1c levels than pa-
tients with T2DM.
RELATIONSHIP BETWEEN T1DM, T2DM, AND DEATH
ACCORDING TO SEX. In men with T1DM, 19% (79 of
420) died during follow-up compared with 24% (73 of
305) among women with T1DM. The adjusted risk of
death was similar among men and women with T1DM:
HR: 1.83 (95% CI: 1.45 to 2.30) and HR: 2.17 (95% CI:
1.66 to 2.84), respectively (Table 3). The absolute risk
TABLE 1 Baseline Characteristics
All Patients No Diabetes T1DM T2DM
Number of patients 39,235 (100) 30,302 (77) 725 (1.8) 8,208 (21)
Age, yrs 67.3  9.2 67.5  9.3 58.8  9.2 67.4  8.4
Female 8,170 (20.8) 5,973 (19.7) 305 (42.1) 1,892 (23.1)
Body mass index, kg/m2 27.3  4.1 26.9  3.9 26.3  4.3 28.8  4.3
eGFR
>60 ml/min/1.73 m2 29,502 (78.7) 23,167 (80.0) 441 (62.8) 5,894 (75.1)
45-60 ml/min/1.73 m2 5,287 (14.1) 3,986 (13.8) 94 (13.4) 1,207 (15.4)
30-44 ml/min/1.73 m2 1,852 (4.9) 1,248 (4.3) 63 (9.0) 541 (6.9)
15-29 ml/min/1.73 m2 369 (1.0) 236 (0.8) 26 (3.7) 107 (1.4)
End-stage renal disease 488 (1.3) 311 (1.1) 78 (11.1) 99 (1.3)
Hypertension 15,749 (40.1) 11,097 (36.6) 358 (49.4) 4,294 (52.3)
Hyperlipidemia 9,626 (24.5) 6,951 (22.9) 201 (27.7) 2,474 (30.1)
Peripheral vascular disease 4,077 (10.4) 2,846 (9.4) 172 (23.7) 1,059 (12.9)
Prior PCI 4,654 (11.9) 3,433 (11.3) 102 (14.1) 1,119 (13.6)
Chronic pulmonary disease 3,090 (7.9) 2,299 (7.6) 41 (5.7) 750 (9.1)
Prior myocardial infarction 21,676 (55.2) 16,527 (54.5) 408 (56.3) 4,741 (57.8)
Heart failure 3,860 (9.8) 2,676 (8.8) 119 (16.4) 1,065 (13.0)
Stroke 3,425 (8.7) 2,449 (8.1) 90 (12.4) 886 (10.8)
Atrial ﬁbrillation 2,555 (6.5) 1,942 (6.4) 24 (3.3) 589 (7.2)
Left ventricular ejection fraction
>50% 26,497 (69.3) 20,840 (70.7) 472 (66.3) 5,185 (64.7)
30%-50% 10,120 (26.5) 7,495 (25.4) 206 (28.9) 2,419 (30.2)
<30% 1,604 (4.2) 1,160 (3.9) 34 (4.8) 410 (5.1)
EuroSCORE 4.1  2.7 4.1  2.7 3.5  2.5 4.2  2.6
Alcohol dependency 902 (2.3) 691 (2.3) 9 (1.2) 202 (2.5)
Birth region
Nordic countries 35,351 (90.1) 27,497 (90.7) 696 (96.0) 7,158 (87.2)
Other 3,883 (9.9) 2,804 (9.3) 29 (4.0) 1,050 (12.8)
Education
<10 yrs 16,668 (43.6) 12,663 (42.9) 239 (33.1) 3,766 (46.9)
10-12 yrs 14,869 (38.9) 11,410 (38.6) 339 (46.9) 3,120 (38.9)
>12 yrs 6,734 (17.6) 5,452 (18.5) 145 (20.1) 1,137 (14.2)
Marital status
Married 25,896 (66.0) 20,127 (66.4) 432 (59.6) 5,337 (65.0)
Other 13,338 (34.0) 10,174 (33.6) 293 (40.4) 2,871 (35.0)
Off-pump CABG 1,309 (3.3) 1,078 (3.6) 17 (2.3) 214 (2.6)
Number of grafts
1-2 6,444 (19.1) 5,167 (19.8) 118 (19.2) 1,159 (16.7)
3-4 23,622 (70.1) 18,207 (69.6) 438 (71.1) 4,977 (71.6)
>4 3,641 (10.8) 2,770 (10.6) 60 (9.7) 811 (11.7)
Type of graft
Internal mammary artery 36,909 (94.1) 28,551 (94.2) 689 (95.0) 7,669 (93.4)
Bilateral internal mammary arteries 468 (1.2) 399 (1.3) 11 (1.5) 58 (0.7)
Radial artery 1,313 (3.3) 1,033 (3.4) 22 (3.0) 258 (3.1)
More than 1 arterial graft 1,718 (4.4) 1,381 (4.6) 31 (4.3) 306 (3.7)
Values are n (%) or mean  SD. End-stage renal disease was deﬁned as eGFR <15 ml/min/1.73 m2 or on dialysis/renal transplant.
CABG ¼ coronary artery bypass grafting; eGFR ¼ estimated glomerular ﬁltration rate; PCI ¼ percutaneous coronary intervention; T1DM ¼ diabetes mellitus type 1;
T2DM ¼ diabetes mellitus type 2.
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1647of death in women with T2DM was higher than that
in men with T2DM (22% vs. 18%). However, after
adjustment for confounders, the relative risks were
similar for both men and women with T2DM (Table 3).
Similar sex-speciﬁc associations between types of
diabetes were also found for death and MACE com-
bined as outcome (Table 3).DISCUSSION
In a large nationwide cohort of patients who under-
went a ﬁrst isolated CABG during an 11-year period in
Sweden, we found that patients with T1DM had a risk
of death after CABG double that of patients without
DM. There was a small, but statistically signiﬁcant,
FIGURE 1 Estimated Survival in Patients Who Underwent Primary Isolated CABG
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Overall Kaplan-Meier estimated survival in 39,235 patients who underwent primary iso-
lated coronary artery bypass grafting (CABG) in Sweden between 2003 and 2013 according
to type of diabetes.
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1648increase in the risk of death in patients with T2DM
when compared with those without DM (Central
Illustration). In addition, there was no difference in
relative risks for death or cardiovascular events be-
tween women and men, neither in those with T1DM
or T2DM.
A number of either population-based or random-
ized trials have reported on the association betweenFIGURE 2 Age-Adjusted Survival of Patients Who Underwent
Primary Isolated CABG
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Age-adjusted survival in 39,235 patients who underwent primary
isolated coronary artery bypass grafting (CABG) in Sweden be-
tween 2003 and 2013 according to type of diabetes.DM and the risk of cardiovascular disease (14). How-
ever, most of these studies have either only included
patients with T2DM or have not made any distinction
between T1DM and T2DM, and thus have analyzed
patients as being merely diabetic or nondiabetic. This
also holds true for previous studies on the importance
of DM for prognosis after CABG, which may explain
the conﬂicting results found in previous studies
(7–11). To the best of our knowledge, only 1 previous
study has investigated the association between T1DM
and T2DM and outcomes after CABG (11), wherein
both subtypes of DM were associated with the com-
bined outcome of death or MI. That study included
only 50 patients with T1DM, and the inclusion period
was 1980 to 1995. Thus, considering the recent rather
steep decline in cardiovascular events and death
associated with DM (19–22), and the small number of
events reported in that study, we believe that the
ﬁndings may not be applicable to contemporary co-
horts of CABG patients.
The 2 main ﬁndings in our study were that T1DM
was associated with a doubling of mortality, but also
that patients with T2DM had only a minimally
increased risk of death in comparison with nondia-
betic patients (Central Illustration). Furthermore, pa-
tients with T1DM were more likely than patients with
T2DM or without diabetes to have comorbidities, such
as chronic kidney disease, end-stage renal disease,
peripheral vascular disease, or heart failure, which all
have been associated with a worse prognosis in dia-
betic patients who undergo CABG (9,10). However,
even after adjustment for these risk factors, the as-
sociation between T1DM and adverse outcome was
signiﬁcant. One of the main differences between the 2
subtypes of diabetes is the duration of the disease. In
the present study, the difference in mean duration of
disease between patients with T1DM and T2DM was
>30 years. This fact may help explain the differences
seen in prognosis between the 2 subtypes of diabetes,
because the duration of exposure to risk factors and
comorbidities was considerably longer in patients
with T1DM than in those with T2DM. In addition,
HbA1c levels were higher in patients with T1DM
than in those with T2DM, revealing poorer glycemic
control in patients with T1DM. The association
between glycemic control and micro- and macro-
angiopathy seems to be more signiﬁcant in T1DM
than in T2DM (16,22). Although we do not have any
data on microvascular complications, the increase in
HbA1c levels together with the longer duration of
diabetes seen in T1DM might explain our ﬁndings.
Interestingly, in a recently published study, HbA1c
levels in patients with insulin-treated DM who un-
derwent PCI were not related to mortality (23). In the
CENTRAL ILLUSTRATION Diabetes and Prognosis After CABG
0.5 1.0 1.5 2.0 2.5
Outcome No. Events/Person-Years
Non-CV Death
No Diabetes (Ref)
Diabetes Type 1
Diabetes Type 2
Death+MACE
No Diabetes (Ref)
Diabetes Type 1
Diabetes Type 2
No Diabetes (Ref)
Diabetes Type 1
Diabetes Type 2
CV Death
No Diabetes (Ref)
Diabetes Type 1
Diabetes Type 2
Repeat Revascularization
No Diabetes (Ref)
Diabetes Type 1
Diabetes Type 2
Death
5,064/179,418
152/3,927
1,549/46,739
2,013/171,155
50/3,640
602/44,000
2,053/171,155
63/3,640
580/44,000
7,831/131,390
239/2,729
2,438/33,157
1,222/157,496
42/3,419
344/40,447
Holzmann, M.J. et al. J Am Coll Cardiol. 2015; 65(16):1644–52.
Outcomes in 39,235 patients who underwent primary isolated coronary artery bypass grafting (CABG) in Sweden between 2003 and
2013, according to type of diabetes. Note: Hazard ratios for CV death, non-CV death, and repeat revascularization are subdistribution
hazard ratios. DeathþMACE is deﬁned as a combined endpoint of death, or rehospitalization for myocardial infarction, heart failure
or stroke, or repeat revascularization. CI ¼ conﬁdence interval; CV ¼ cardiovascular; MACE ¼ major adverse cardiac event(s);
Ref ¼ reference category.
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1649same study, patients with DM without insulin
treatment were more likely to beneﬁt from better
glycemic control. However, the investigators were
unable to subtype their patients into T1DM or T2DM,
but only into treatment groups with or without
insulin. Furthermore, in a recently published study
from the same register where our T1DM patients
were retrieved, even those T1DM patients who had a
HbA1c level below 7.0% had a more than doubled
risk of death as compared with the general popula-
tion (24). This indicates that even with optimal gly-
cemic control T1DM patients are at high risk of
premature death.
We found only a small increase in the risk of death
in patients with T2DM when compared with those
without DM. This ﬁnding may have several expla-
nations. First, previous studies have suggested that
a large proportion of patients with MI have eitherglucose intolerance or established T2DM, which has
gone undetected until they are admitted for an acute
coronary syndrome (24). Thus, if a large proportion
of patients were categorized as non-DM patients and
truly had either glucose intolerance or established
T2DM, and this was related to outcome, this may
have diluted the associations seen between both
T2DM and T1DM and the outcome measures. How-
ever, studies that have investigated the prognostic
importance of glucose intolerance in patients with
MI have failed to show any convincing associations
with adverse outcomes (25). Second, because all pa-
tients with T2DM already had established coronary
artery disease, and as a consequence a very high risk
of recurrent cardiovascular events, they may have
been treated with optimal medications and measures
to reduce their risk of future cardiovascular events
(26). Their treatment may even have been better
TABLE 3 Absolute a
Primary Isolated CAB
DM Stratiﬁed by Sex
Death
Men
Crude rate per 1,000
person-yrs
Crude HR
Adjusted HR
Women
Crude rate per 1,000
person-yrs
Crude HR
Adjusted HR
MACEþdeath*
Men
Crude rate per 1,000
person-yrs
Crude HR
Adjusted HR
Women
Crude rate per 1,000
person-years
Crude HR
Adjusted HR
Values are n events/n patie
the ﬁnal multivariable mod
myocardial infarction, hear
CI ¼ conﬁdence interval
in Table 1.
TABLE 2 HbA1c and DM Duration in Patients With T1DM and T2DM
T1DM
n ¼ 725
T2DM
n ¼ 8,208
Diabetes duration 40.8  12.3 9.6  8.1
#20 yrs 44 (6.1) 7,351 (89.6)
>20 yrs 681 (93.9) 857 (10.4)
HbA1c IFCC
(mmol/mol)
NGSP
(%)
IFCC, mmol/mol 67.8  10.7 57.9  12.0
NGSP, % 8.4  1.0 7.4  1.1
<53 <7.0 52 (7.2) 3,053 (37.3)
53–73 7.0–8.8 460 (63.5) 4,264 (52.2)
>73 >8.8 212 (29.3) 858 (10.5)
Values are mean  SD or n (%), unless otherwise noted. All p values <0.001.
DM ¼ diabetes mellitus; HbA1c ¼ glycosylated hemoglobin; IFCC ¼ International Federation of
Clinical Chemistry; NGSP ¼ National Glycohemoglobin Standardization Program; other abbrevi-
ations as in Table 1.
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1650than that for patients without DM, thus diluting the
differences in risk between those with T2DM and
those without DM.
It is generally thought that women with DM have a
higher relative risk of cardiovascular events than men
with DM (12,27,28). However, recent studies have
challenged this statement and have found similarnd Relative Risks of Death or MACEþDeath After
G in Patients With T1DM or T2DM Compared With Patients Without
No DM T1DM T2DM
3,918/24,329 (16.1) 79/420 (18.8) 1,134/6,316 (17.9)
27.3 (26.5–28.2) 34.1 (27.3–42.5) 31.7 (29.9–33.6)
1.00 1.28 (1.02–1.60) 1.18 (1.10–1.26)
1.00 1.83 (1.45–2.30) 1.09 (1.02–1.17)
1,146/5,973 (19.2) 73/305 (23.9) 415/1,892 (21.9)
31.8 (30.0–33.7) 45.4 (36.1–57.1) 37.8 (34.4–41.7)
1.00 1.46 (1.15–1.85) 1.21 (1.08–1.35)
1.00 2.17 (1.66–2.84) 1.18 (1.04–1.32)
6,070/22,777 (26.7) 123/391 (31.5) 1,821/5,887 (30.9)
57.6 (56.2–59.1) 75.4 (63.2–90.0) 71.9 (68.7–75.3)
1.00 1.30 (1.08–1.55) 1.24 (1.17–1.30)
1.00 1.51 (1.26–1.82) 1.14 (1.08–1.21)
1,761/5,635 (31.2) 116/282 (41.1) 617/1,790 (34.5)
67.6 (64.6–70.9) 106 (88.1–127) 78.7 (72.7–85.2)
1.00 1.51 (1.25–1.82) 1.15 (1.05–1.26)
1.00 1.75 (1.42–2.16) 1.10 (1.00-1.21)
nts (%) or HR (95% CI). All variables listed in Table 1 were included as covariates in
el. *MACEþdeath is deﬁned as a combined endpoint of death, or rehospitalization for
t failure, or stroke, or repeat revascularization.
; HR ¼ hazard ratio; MACE ¼ major adverse cardiac event(s); other abbreviations asrisks in men and women (19). In the present study, we
found no sex differences in relative risks between
outcomes and both T1DM and T2DM cohorts.
By using the National Diabetes Register, we were
able to classify all patients according to the type
of DM, and thus investigate the importance of the
2 subtypes for prognosis. The information used for
categorization into T1DM and T2DM has been shown
to have high validity (16). To the best of our knowl-
edge, this was the ﬁrst study of a contemporary cohort
of patients undergoing CABG where the association
between subtypes of DM and prognosis were investi-
gated. Moreover, we also had information on the
characteristics that distinguish T1DM from T2DM in
general, that is, duration of diabetes and glycemic
control, which allowed us to speculate to some extent
on potential mechanisms responsible for the differ-
ences seen in prognosis among patients with T1DM
and T2DM. The nationwide population-based design
allowed for a large study population, and the rather
long follow-up led to a large number of events, which
gave us the opportunity to analyze additional clini-
cally relevant outcomes, such as cause-speciﬁc mor-
tality and need for repeat revascularization. The
high-quality Swedish national registers from which
we derived the study population and retrieved pa-
tient characteristics and outcomes have been found
to have high validity in previous studies (15,29,30).
Furthermore, as the coverage of these registers is
virtually complete and countrywide, the risk of
misclassiﬁcation of disease or outcome was small,
and there was no loss to follow-up. In addition,
considering the nationwide design of our study and
the recent study period, reﬂecting current standard
of care, we believe that our results have a high
external validity and are applicable to other patients
with DM undergoing CABG in countries with a
similar level of healthcare.
STUDY LIMITATIONS. We did not have any informa-
tion on patients with DM who underwent PCI instead
of CABG for multivessel disease. Therefore, our re-
sults cannot be generalized to this group of patients.
However, a number of early and recent studies have
investigated which method of revascularization (PCI
or CABG) is preferred in patients with DM (31). There
is a general consensus that CABG is superior to PCI in
patients with DM and multivessel disease, particu-
larly in patients with more complex coronary artery
disease, provided that they are candidates for cardiac
surgery (32). Thus, we believe that our ﬁndings are of
great importance for patients with DM who may need
to undergo multivessel revascularization.
There may have been misclassiﬁcation of glyce-
mic control among patients without DM. This was
PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE: Patients with
type 1 diabetes mellitus have a greater risk of death and car-
diovascular events after CABG surgery than patients without
diabetes, but these risks are only marginally increased among
patients with type 2 diabetes.
TRANSLATIONAL OUTLOOK: Future studies should attempt
to deﬁne the speciﬁc types and timing of secondary prevention
measures that best mitigate the risk of adverse outcomes for
patients with diabetes undergoing CABG surgery.
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1651a potential limitation because it has been shown
that a large proportion of patients with acute coro-
nary syndromes have undetected T2DM or glucose
intolerance (24).
CONCLUSIONS
We found that patients with T1DM had a doubling of
the risk of death, whereas patients with T2DM had
almost a similar risk of death as patients without
diabetes in a nationwide cohort of 39,235 patients
who underwent CABG. Our data indicate that pa-
tients with T1DM are at high risk for adverse out-
come after CABG and should be closely followed up,
and that all possible measures to mitigate their risk
of death or recurrent cardiovascular events should
be instituted.
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